Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Inmed Pharmaceuticals Inc (INM)

Inmed Pharmaceuticals Inc (INM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,979
  • Shares Outstanding, K 2,919
  • Annual Sales, $ 4,940 K
  • Annual Income, $ -8,160 K
  • EBIT $ -8 M
  • EBITDA $ -7 M
  • 60-Month Beta 0.52
  • Price/Sales 0.40
  • Price/Cash Flow N/A
  • Price/Book 0.20
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.89
  • Most Recent Earnings $-0.51 on 02/11/26
  • Next Earnings Date 05/11/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5750 +17.91%
on 03/31/26
0.9529 -28.85%
on 03/04/26
-0.1420 (-17.32%)
since 03/02/26
3-Month
0.5750 +17.91%
on 03/31/26
1.4000 -51.57%
on 01/09/26
-0.4420 (-39.46%)
since 01/02/26
52-Week
0.5750 +17.91%
on 03/31/26
7.9800 -91.50%
on 06/02/25
-1.4020 (-67.40%)
since 04/02/25

Most Recent Stories

More News
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

Vancouver, British Columbia--(Newsfile Corp. - March 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying...

INM : 0.6780 (+1.15%)
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program

Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical TrialsConsistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to Three-Dimensional...

INM : 0.6780 (+1.15%)
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling ActivitiesTargeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027Vancouver,...

INM : 0.6780 (+1.15%)
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

Vancouver, British Columbia--(Newsfile Corp. - March 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying...

INM : 0.6780 (+1.15%)
InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

Vancouver, British Columbia--(Newsfile Corp. - February 11, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing...

INM : 0.6780 (+1.15%)
InMed Announces Results of 2025 Annual General and Special Meeting

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary...

INM : 0.6780 (+1.15%)
InMed Provides Update on BayMedica Commercial Business

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary...

INM : 0.6780 (+1.15%)
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

Data demonstrate a favorable bioavailability profile of INM-901 oral formulationData will support design and planning of first in human clinical trialsPreparing for pre-IND meeting with the FDA Vancouver,...

INM : 0.6780 (+1.15%)
InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Vancouver, British Columbia--(Newsfile Corp. - November 6, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a...

INM : 0.6780 (+1.15%)
InMed Pharmaceuticals Strengthens Board with Strategic Appointment

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. InMed Pharmaceuticals...

INM : 0.6780 (+1.15%)

Business Summary

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It engages in developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol in diseases with unmet medical need. InMed Pharmaceuticals Inc. is based in VANCOUVER, BC.

See More

Key Turning Points

3rd Resistance Point 0.7394
2nd Resistance Point 0.7099
1st Resistance Point 0.6940
Last Price 0.6780
1st Support Level 0.6486
2nd Support Level 0.6191
3rd Support Level 0.6032

See More

52-Week High 7.9800
Fibonacci 61.8% 5.1513
Fibonacci 50% 4.2775
Fibonacci 38.2% 3.4037
Last Price 0.6780
52-Week Low 0.5750

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.